ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

NCT04578613 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

218

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: ICP-022
DRUG: Chlorambucil
DRUG: Rituximab

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.